Share Price and Basic Stock Data
Last Updated: November 17, 2025, 8:49 pm
| PEG Ratio | 5.53 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Fortis Healthcare Ltd operates within the Hospitals & Medical Services industry and has established itself as a significant player in the Indian healthcare sector. The company reported a market capitalization of ₹79,799 Cr and a current share price of ₹1,057. Fortis has demonstrated robust revenue growth over recent years, with sales increasing from ₹5,718 Cr in FY 2022 to ₹6,298 Cr in FY 2023, and further anticipated to reach ₹7,783 Cr in FY 2025. The latest quarterly data indicates a steady upward trend, with sales of ₹1,657 Cr in June 2023, rising to ₹1,770 Cr in September 2023. This growth trajectory highlights the company’s ability to capitalize on the rising demand for healthcare services, supported by an increasing population and heightened health awareness, making it a potentially lucrative investment in the healthcare sector.
Profitability and Efficiency Metrics
Fortis Healthcare’s profitability metrics reflect a mixed performance, with a reported net profit of ₹902 Cr for the most recent fiscal year. The company’s operating profit margin (OPM) stood at 23%, illustrating efficient cost management relative to peers in the sector. The quarterly OPM figures have shown fluctuations, with a notable increase to 22% in September 2024, indicating improved operational efficiency. However, the price-to-earnings (P/E) ratio of 86.7 suggests that the stock may be overvalued compared to industry norms, which typically range lower. The return on equity (ROE) is reported at 10.1%, while the return on capital employed (ROCE) is slightly higher at 12%. These figures suggest that while Fortis is generating decent returns, there is room for improvement in enhancing shareholder value and operational efficiency.
Balance Sheet Strength and Financial Ratios
Fortis Healthcare’s balance sheet reveals a mix of strengths and weaknesses. The company holds reserves of ₹8,162 Cr against borrowings of ₹2,475 Cr, resulting in a low debt-to-equity ratio of 0.24, indicating prudent financial management. The interest coverage ratio (ICR) of 8.97x further underscores the company’s ability to meet its interest obligations comfortably. However, the current ratio of 0.91 suggests potential liquidity concerns, as it is below the desirable threshold of 1. The cash conversion cycle (CCC) stands at -101 days, indicating efficient working capital management. Additionally, the price-to-book value (P/BV) ratio of 5.91x may signal overvaluation when compared to typical sector ranges, necessitating caution for prospective investors.
Shareholding Pattern and Investor Confidence
The shareholding structure of Fortis Healthcare indicates a diversified ownership base, with promoters holding 31.17% of the company. Foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold 27.18% and 29.79%, respectively, reflecting strong institutional interest and confidence in the company’s prospects. The public shareholding stands at 11.87%, with the number of shareholders reported at 2,05,373. This distribution suggests a healthy mix of long-term and institutional investors, which can stabilize the stock price. Despite some fluctuations in FII and DII holdings over time, the overall investor confidence remains robust, supported by recent performance metrics and growth prospects in the healthcare sector.
Outlook, Risks, and Final Insight
Looking ahead, Fortis Healthcare has several growth opportunities, particularly in expanding its network and enhancing service offerings to meet increasing healthcare demands. However, risks such as regulatory changes, rising operational costs, and competition from emerging healthcare providers may pose challenges. The company’s ability to navigate these risks while capitalizing on growth opportunities will be crucial for sustaining its upward trajectory. Additionally, improving profitability metrics and further strengthening the balance sheet will be essential for enhancing shareholder value. Overall, Fortis Healthcare presents a compelling case for investors, but due diligence is warranted given the inherent sector risks and the company’s elevated valuation ratios.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Fortis Healthcare Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 45.8 Cr. | 137 | 195/125 | 9.35 | 117 | 2.56 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 23.5 Cr. | 22.4 | 35.5/0.00 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 13.4 Cr. | 12.9 | 21.4/11.6 | 148 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 121 Cr. | 64.6 | 98.7/52.0 | 26.7 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 21.4 Cr. | 3.97 | 7.60/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 27,940.50 Cr | 851.94 | 103.08 | 99.08 | 0.31% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,488 | 1,607 | 1,560 | 1,643 | 1,657 | 1,770 | 1,680 | 1,786 | 1,859 | 1,988 | 1,928 | 2,007 | 2,167 |
| Expenses | 1,237 | 1,304 | 1,283 | 1,372 | 1,386 | 1,440 | 1,396 | 1,405 | 1,516 | 1,554 | 1,553 | 1,572 | 1,676 |
| Operating Profit | 251 | 303 | 276 | 271 | 272 | 330 | 284 | 381 | 343 | 435 | 375 | 435 | 491 |
| OPM % | 17% | 19% | 18% | 16% | 16% | 19% | 17% | 21% | 18% | 22% | 19% | 22% | 23% |
| Other Income | 31 | 75 | 26 | 26 | 10 | 18 | 19 | 17 | 14 | -42 | 47 | -29 | 31 |
| Interest | 31 | 33 | 33 | 32 | 31 | 32 | 33 | 35 | 35 | 36 | 45 | 68 | 70 |
| Depreciation | 74 | 77 | 83 | 82 | 79 | 84 | 87 | 92 | 91 | 95 | 97 | 102 | 101 |
| Profit before tax | 176 | 268 | 186 | 183 | 171 | 233 | 183 | 271 | 230 | 261 | 279 | 237 | 351 |
| Tax % | 24% | 19% | 24% | 25% | 27% | 21% | 27% | 25% | 24% | 26% | 9% | 21% | 24% |
| Net Profit | 134 | 218 | 142 | 138 | 124 | 184 | 134 | 203 | 174 | 193 | 254 | 188 | 267 |
| EPS in Rs | 1.62 | 2.71 | 1.72 | 1.76 | 1.48 | 2.30 | 1.78 | 2.37 | 2.20 | 2.34 | 3.28 | 2.44 | 3.45 |
Last Updated: August 20, 2025, 10:45 am
Below is a detailed analysis of the quarterly data for Fortis Healthcare Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 2,167.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,007.00 Cr. (Mar 2025) to 2,167.00 Cr., marking an increase of 160.00 Cr..
- For Expenses, as of Jun 2025, the value is 1,676.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,572.00 Cr. (Mar 2025) to 1,676.00 Cr., marking an increase of 104.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 491.00 Cr.. The value appears strong and on an upward trend. It has increased from 435.00 Cr. (Mar 2025) to 491.00 Cr., marking an increase of 56.00 Cr..
- For OPM %, as of Jun 2025, the value is 23.00%. The value appears strong and on an upward trend. It has increased from 22.00% (Mar 2025) to 23.00%, marking an increase of 1.00%.
- For Other Income, as of Jun 2025, the value is 31.00 Cr.. The value appears strong and on an upward trend. It has increased from -29.00 Cr. (Mar 2025) to 31.00 Cr., marking an increase of 60.00 Cr..
- For Interest, as of Jun 2025, the value is 70.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 68.00 Cr. (Mar 2025) to 70.00 Cr., marking an increase of 2.00 Cr..
- For Depreciation, as of Jun 2025, the value is 101.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 102.00 Cr. (Mar 2025) to 101.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 351.00 Cr.. The value appears strong and on an upward trend. It has increased from 237.00 Cr. (Mar 2025) to 351.00 Cr., marking an increase of 114.00 Cr..
- For Tax %, as of Jun 2025, the value is 24.00%. The value appears to be increasing, which may not be favorable. It has increased from 21.00% (Mar 2025) to 24.00%, marking an increase of 3.00%.
- For Net Profit, as of Jun 2025, the value is 267.00 Cr.. The value appears strong and on an upward trend. It has increased from 188.00 Cr. (Mar 2025) to 267.00 Cr., marking an increase of 79.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 3.45. The value appears strong and on an upward trend. It has increased from 2.44 (Mar 2025) to 3.45, marking an increase of 1.01.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 5:23 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,492 | 3,966 | 4,199 | 4,574 | 4,561 | 4,469 | 4,632 | 4,030 | 5,718 | 6,298 | 6,893 | 7,783 | 8,434 |
| Expenses | 3,430 | 3,857 | 4,106 | 4,220 | 4,287 | 4,238 | 4,022 | 3,626 | 4,649 | 5,196 | 5,625 | 6,195 | 6,576 |
| Operating Profit | 62 | 109 | 92 | 354 | 274 | 231 | 610 | 404 | 1,069 | 1,101 | 1,268 | 1,588 | 1,858 |
| OPM % | 2% | 3% | 2% | 8% | 6% | 5% | 13% | 10% | 19% | 17% | 18% | 20% | 22% |
| Other Income | 152 | 92 | 299 | 649 | -689 | 228 | 126 | 95 | 367 | 157 | 64 | -11 | 98 |
| Interest | 250 | 152 | 133 | 229 | 258 | 337 | 205 | 166 | 147 | 129 | 131 | 184 | 257 |
| Depreciation | 183 | 235 | 225 | 222 | 239 | 233 | 292 | 291 | 301 | 316 | 342 | 386 | 407 |
| Profit before tax | -219 | -185 | 34 | 552 | -912 | -110 | 239 | 43 | 988 | 814 | 858 | 1,007 | 1,292 |
| Tax % | 5% | 2% | -24% | 13% | 2% | 103% | 62% | 230% | 20% | 22% | 25% | 20% | |
| Net Profit | -218 | -130 | 42 | 479 | -934 | -224 | 91 | -56 | 790 | 633 | 645 | 809 | 1,038 |
| EPS in Rs | -4.73 | -3.10 | 0.40 | 8.14 | -19.46 | -3.96 | 0.77 | -1.45 | 7.35 | 7.80 | 7.93 | 10.26 | 13.43 |
| Dividend Payout % | -0% | -1% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 13% | 13% | 10% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 40.37% | 132.31% | 1040.48% | -294.99% | 76.02% | 140.62% | -161.54% | 1510.71% | -19.87% | 1.90% | 25.43% |
| Change in YoY Net Profit Growth (%) | 0.00% | 91.94% | 908.17% | -1335.47% | 371.01% | 64.61% | -302.16% | 1672.25% | -1530.59% | 21.77% | 23.53% |
Fortis Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 11% |
| 3 Years: | 11% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 70% |
| 3 Years: | 31% |
| TTM: | 43% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 48% |
| 3 Years: | 49% |
| 1 Year: | 69% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 6% |
| 3 Years: | 9% |
| Last Year: | 10% |
Last Updated: September 5, 2025, 4:15 am
Balance Sheet
Last Updated: July 25, 2025, 3:14 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 463 | 463 | 463 | 518 | 519 | 755 | 755 | 755 | 755 | 755 | 755 | 755 |
| Reserves | 3,820 | 3,585 | 3,998 | 4,626 | 3,543 | 5,846 | 5,906 | 5,365 | 5,423 | 6,487 | 6,908 | 8,162 |
| Borrowings | 2,550 | 1,784 | 1,513 | 2,217 | 1,962 | 2,010 | 1,594 | 1,531 | 1,255 | 926 | 1,155 | 2,475 |
| Other Liabilities | 1,018 | 1,760 | 1,257 | 2,227 | 2,455 | 2,875 | 2,781 | 3,216 | 4,082 | 3,921 | 4,153 | 1,985 |
| Total Liabilities | 7,851 | 7,592 | 7,232 | 9,588 | 8,479 | 11,486 | 11,036 | 10,866 | 11,516 | 12,089 | 12,971 | 13,377 |
| Fixed Assets | 4,147 | 4,218 | 3,642 | 5,419 | 4,992 | 8,477 | 8,802 | 8,799 | 9,416 | 9,426 | 9,874 | 10,424 |
| CWIP | 147 | 228 | 226 | 268 | 226 | 450 | 204 | 165 | 193 | 228 | 542 | 407 |
| Investments | 1,817 | 1,464 | 1,452 | 1,878 | 1,732 | 270 | 175 | 186 | 104 | 210 | 230 | 169 |
| Other Assets | 1,739 | 1,682 | 1,913 | 2,023 | 1,529 | 2,290 | 1,856 | 1,716 | 1,803 | 2,225 | 2,326 | 2,378 |
| Total Assets | 7,851 | 7,592 | 7,232 | 9,588 | 8,479 | 11,486 | 11,036 | 10,866 | 11,516 | 12,089 | 12,971 | 13,377 |
Below is a detailed analysis of the balance sheet data for Fortis Healthcare Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 755.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 755.00 Cr..
- For Reserves, as of Mar 2025, the value is 8,162.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,908.00 Cr. (Mar 2024) to 8,162.00 Cr., marking an increase of 1,254.00 Cr..
- For Borrowings, as of Mar 2025, the value is 2,475.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 1,155.00 Cr. (Mar 2024) to 2,475.00 Cr., marking an increase of 1,320.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 1,985.00 Cr.. The value appears to be improving (decreasing). It has decreased from 4,153.00 Cr. (Mar 2024) to 1,985.00 Cr., marking a decrease of 2,168.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 13,377.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 12,971.00 Cr. (Mar 2024) to 13,377.00 Cr., marking an increase of 406.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 10,424.00 Cr.. The value appears strong and on an upward trend. It has increased from 9,874.00 Cr. (Mar 2024) to 10,424.00 Cr., marking an increase of 550.00 Cr..
- For CWIP, as of Mar 2025, the value is 407.00 Cr.. The value appears to be declining and may need further review. It has decreased from 542.00 Cr. (Mar 2024) to 407.00 Cr., marking a decrease of 135.00 Cr..
- For Investments, as of Mar 2025, the value is 169.00 Cr.. The value appears to be declining and may need further review. It has decreased from 230.00 Cr. (Mar 2024) to 169.00 Cr., marking a decrease of 61.00 Cr..
- For Other Assets, as of Mar 2025, the value is 2,378.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,326.00 Cr. (Mar 2024) to 2,378.00 Cr., marking an increase of 52.00 Cr..
- For Total Assets, as of Mar 2025, the value is 13,377.00 Cr.. The value appears strong and on an upward trend. It has increased from 12,971.00 Cr. (Mar 2024) to 13,377.00 Cr., marking an increase of 406.00 Cr..
Notably, the Reserves (8,162.00 Cr.) exceed the Borrowings (2,475.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 60.00 | 108.00 | 91.00 | 352.00 | 273.00 | 229.00 | 609.00 | 403.00 | 0.00 | -925.00 | 0.00 | -1.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 46 | 38 | 39 | 38 | 38 | 44 | 36 | 41 | 33 | 34 | 33 | 37 |
| Inventory Days | 26 | 25 | 23 | 23 | 24 | 22 | 30 | 29 | 33 | 31 | 24 | 23 |
| Days Payable | 200 | 207 | 218 | 215 | 279 | 296 | 226 | 205 | 178 | 179 | 164 | 161 |
| Cash Conversion Cycle | -128 | -144 | -156 | -155 | -217 | -230 | -161 | -135 | -112 | -115 | -107 | -101 |
| Working Capital Days | -19 | -71 | -69 | -87 | -113 | -234 | -150 | -56 | -35 | -22 | -124 | -30 |
| ROCE % | 0% | -0% | 3% | 11% | 3% | 6% | 4% | 2% | 10% | 10% | 10% | 12% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Mid-Cap Opportunities Fund - Regular Plan | 21,353,375 | 1.44 | 1015.03 | 21,353,375 | 2025-04-22 13:31:13 | 0% |
| Kotak Emerging Equity Fund - Regular Plan | 20,190,278 | 1.96 | 959.74 | 20,190,278 | 2025-04-22 17:25:35 | 0% |
| Axis Midcap Fund | 13,299,371 | 2.1 | 632.19 | 13,299,371 | 2025-04-22 17:25:35 | 0% |
| Nippon India Growth Fund | 13,200,000 | 2.03 | 627.46 | 13,200,000 | 2025-04-22 17:25:35 | 0% |
| HDFC Small Cap Fund - Regular Plan | 12,453,275 | 1.88 | 591.97 | 12,453,275 | 2025-04-22 17:25:35 | 0% |
| Mirae Asset Large & Midcap Fund | 9,491,563 | 1.19 | 451.18 | 9,491,563 | 2025-04-22 17:25:35 | 0% |
| Aditya Birla Sun Life ELSS Tax Saver Fund | 8,360,144 | 2.44 | 397.4 | 8,360,144 | 2025-04-22 17:25:35 | 0% |
| Mirae Asset Midcap Fund | 7,435,461 | 2.12 | 353.44 | 7,435,461 | 2025-04-22 17:25:35 | 0% |
| SBI Long Term Equity Fund | 7,065,304 | 1.3 | 335.85 | 7,065,304 | 2025-04-22 17:25:35 | 0% |
| Kotak Multicap Fund | 5,485,043 | 1.97 | 260.73 | 5,485,043 | 2025-04-22 17:25:35 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 10.26 | 7.93 | 7.80 | 7.35 | -1.45 |
| Diluted EPS (Rs.) | 10.26 | 7.93 | 7.80 | 7.35 | -1.45 |
| Cash EPS (Rs.) | 15.68 | 12.96 | 12.28 | 14.13 | 2.48 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 118.11 | 113.33 | 107.30 | 92.83 | 88.98 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 118.11 | 113.33 | 107.30 | 92.83 | 88.98 |
| Revenue From Operations / Share (Rs.) | 103.09 | 91.30 | 83.42 | 75.73 | 53.38 |
| PBDIT / Share (Rs.) | 21.92 | 17.30 | 15.40 | 14.52 | 5.97 |
| PBIT / Share (Rs.) | 16.81 | 12.76 | 11.22 | 10.54 | 2.12 |
| PBT / Share (Rs.) | 13.19 | 11.24 | 10.49 | 12.76 | -0.05 |
| Net Profit / Share (Rs.) | 10.57 | 8.42 | 8.10 | 10.14 | -1.37 |
| NP After MI And SOA / Share (Rs.) | 10.26 | 7.93 | 7.80 | 7.35 | -1.45 |
| PBDIT Margin (%) | 21.26 | 18.94 | 18.46 | 19.17 | 11.19 |
| PBIT Margin (%) | 16.30 | 13.97 | 13.45 | 13.91 | 3.98 |
| PBT Margin (%) | 12.79 | 12.30 | 12.57 | 16.85 | -0.10 |
| Net Profit Margin (%) | 10.25 | 9.22 | 9.70 | 13.39 | -2.57 |
| NP After MI And SOA Margin (%) | 9.94 | 8.68 | 9.34 | 9.70 | -2.72 |
| Return on Networth / Equity (%) | 8.68 | 7.81 | 8.12 | 8.98 | -1.79 |
| Return on Capital Employeed (%) | 10.50 | 9.52 | 7.69 | 7.49 | 1.61 |
| Return On Assets (%) | 5.65 | 4.50 | 4.73 | 4.67 | -0.98 |
| Long Term Debt / Equity (X) | 0.23 | 0.09 | 0.07 | 0.12 | 0.15 |
| Total Debt / Equity (X) | 0.24 | 0.11 | 0.09 | 0.15 | 0.18 |
| Asset Turnover Ratio (%) | 0.57 | 0.53 | 0.09 | 0.07 | 0.05 |
| Current Ratio (X) | 0.91 | 0.44 | 0.98 | 0.89 | 0.84 |
| Quick Ratio (X) | 0.84 | 0.41 | 0.90 | 0.79 | 0.77 |
| Inventory Turnover Ratio (X) | 69.89 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 9.99 | 12.60 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 6.67 | 8.01 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 90.01 | 87.40 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 93.33 | 91.99 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 8.97 | 9.97 | 9.01 | 7.47 | 2.72 |
| Interest Coverage Ratio (Post Tax) (X) | 5.81 | 5.73 | 5.16 | 4.07 | 0.36 |
| Enterprise Value (Cr.) | 54674.02 | 32853.83 | 20823.69 | 23306.97 | 16352.45 |
| EV / Net Operating Revenue (X) | 7.03 | 4.77 | 3.31 | 4.08 | 4.06 |
| EV / EBITDA (X) | 33.04 | 25.16 | 17.90 | 21.26 | 36.26 |
| MarketCap / Net Operating Revenue (X) | 6.78 | 4.60 | 3.12 | 3.83 | 3.73 |
| Retention Ratios (%) | 90.00 | 87.39 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 5.91 | 4.14 | 2.71 | 3.55 | 2.45 |
| Price / Net Operating Revenue (X) | 6.78 | 4.60 | 3.12 | 3.83 | 3.73 |
| EarningsYield | 0.01 | 0.01 | 0.02 | 0.02 | -0.01 |
After reviewing the key financial ratios for Fortis Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 10.26. This value is within the healthy range. It has increased from 7.93 (Mar 24) to 10.26, marking an increase of 2.33.
- For Diluted EPS (Rs.), as of Mar 25, the value is 10.26. This value is within the healthy range. It has increased from 7.93 (Mar 24) to 10.26, marking an increase of 2.33.
- For Cash EPS (Rs.), as of Mar 25, the value is 15.68. This value is within the healthy range. It has increased from 12.96 (Mar 24) to 15.68, marking an increase of 2.72.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 118.11. It has increased from 113.33 (Mar 24) to 118.11, marking an increase of 4.78.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 118.11. It has increased from 113.33 (Mar 24) to 118.11, marking an increase of 4.78.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 103.09. It has increased from 91.30 (Mar 24) to 103.09, marking an increase of 11.79.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 21.92. This value is within the healthy range. It has increased from 17.30 (Mar 24) to 21.92, marking an increase of 4.62.
- For PBIT / Share (Rs.), as of Mar 25, the value is 16.81. This value is within the healthy range. It has increased from 12.76 (Mar 24) to 16.81, marking an increase of 4.05.
- For PBT / Share (Rs.), as of Mar 25, the value is 13.19. This value is within the healthy range. It has increased from 11.24 (Mar 24) to 13.19, marking an increase of 1.95.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 10.57. This value is within the healthy range. It has increased from 8.42 (Mar 24) to 10.57, marking an increase of 2.15.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 10.26. This value is within the healthy range. It has increased from 7.93 (Mar 24) to 10.26, marking an increase of 2.33.
- For PBDIT Margin (%), as of Mar 25, the value is 21.26. This value is within the healthy range. It has increased from 18.94 (Mar 24) to 21.26, marking an increase of 2.32.
- For PBIT Margin (%), as of Mar 25, the value is 16.30. This value is within the healthy range. It has increased from 13.97 (Mar 24) to 16.30, marking an increase of 2.33.
- For PBT Margin (%), as of Mar 25, the value is 12.79. This value is within the healthy range. It has increased from 12.30 (Mar 24) to 12.79, marking an increase of 0.49.
- For Net Profit Margin (%), as of Mar 25, the value is 10.25. This value exceeds the healthy maximum of 10. It has increased from 9.22 (Mar 24) to 10.25, marking an increase of 1.03.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 9.94. This value is within the healthy range. It has increased from 8.68 (Mar 24) to 9.94, marking an increase of 1.26.
- For Return on Networth / Equity (%), as of Mar 25, the value is 8.68. This value is below the healthy minimum of 15. It has increased from 7.81 (Mar 24) to 8.68, marking an increase of 0.87.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.50. This value is within the healthy range. It has increased from 9.52 (Mar 24) to 10.50, marking an increase of 0.98.
- For Return On Assets (%), as of Mar 25, the value is 5.65. This value is within the healthy range. It has increased from 4.50 (Mar 24) to 5.65, marking an increase of 1.15.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.23. This value is within the healthy range. It has increased from 0.09 (Mar 24) to 0.23, marking an increase of 0.14.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.24. This value is within the healthy range. It has increased from 0.11 (Mar 24) to 0.24, marking an increase of 0.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.57. It has increased from 0.53 (Mar 24) to 0.57, marking an increase of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 0.91. This value is below the healthy minimum of 1.5. It has increased from 0.44 (Mar 24) to 0.91, marking an increase of 0.47.
- For Quick Ratio (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has increased from 0.41 (Mar 24) to 0.84, marking an increase of 0.43.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 69.89. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 69.89, marking an increase of 69.89.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 9.99. This value is below the healthy minimum of 20. It has decreased from 12.60 (Mar 24) to 9.99, marking a decrease of 2.61.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 6.67. This value is below the healthy minimum of 20. It has decreased from 8.01 (Mar 24) to 6.67, marking a decrease of 1.34.
- For Earning Retention Ratio (%), as of Mar 25, the value is 90.01. This value exceeds the healthy maximum of 70. It has increased from 87.40 (Mar 24) to 90.01, marking an increase of 2.61.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 93.33. This value exceeds the healthy maximum of 70. It has increased from 91.99 (Mar 24) to 93.33, marking an increase of 1.34.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.97. This value is within the healthy range. It has decreased from 9.97 (Mar 24) to 8.97, marking a decrease of 1.00.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.81. This value is within the healthy range. It has increased from 5.73 (Mar 24) to 5.81, marking an increase of 0.08.
- For Enterprise Value (Cr.), as of Mar 25, the value is 54,674.02. It has increased from 32,853.83 (Mar 24) to 54,674.02, marking an increase of 21,820.19.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.03. This value exceeds the healthy maximum of 3. It has increased from 4.77 (Mar 24) to 7.03, marking an increase of 2.26.
- For EV / EBITDA (X), as of Mar 25, the value is 33.04. This value exceeds the healthy maximum of 15. It has increased from 25.16 (Mar 24) to 33.04, marking an increase of 7.88.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 6.78. This value exceeds the healthy maximum of 3. It has increased from 4.60 (Mar 24) to 6.78, marking an increase of 2.18.
- For Retention Ratios (%), as of Mar 25, the value is 90.00. This value exceeds the healthy maximum of 70. It has increased from 87.39 (Mar 24) to 90.00, marking an increase of 2.61.
- For Price / BV (X), as of Mar 25, the value is 5.91. This value exceeds the healthy maximum of 3. It has increased from 4.14 (Mar 24) to 5.91, marking an increase of 1.77.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 6.78. This value exceeds the healthy maximum of 3. It has increased from 4.60 (Mar 24) to 6.78, marking an increase of 2.18.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fortis Healthcare Ltd:
- Net Profit Margin: 10.25%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.5% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 8.68% (Industry Average ROE: 14.16%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.81
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.84
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 70.8 (Industry average Stock P/E: 85.15)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.24
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 10.25%
Fundamental Analysis of Fortis Healthcare Ltd
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Fortis Hospital, Mohali Punjab 160062 | secretarial@fortishealthcare.com http://www.fortishealthcare.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ravi Rajagopal | Chairman & Ind.Director |
| Dr. Ashutosh Raghuvanshi | Managing Director & CEO |
| Ms. Suvalaxmi Chakraborty | Independent Director |
| Mr. Indrajit Banerjee | Independent Director |
| Ms. Shailaja Chandra | Independent Director |
| Mr. Tomo Nagahiro | Non Executive Director |
| Mr. Dilip Kadambi | Non Executive Director |
| Mr. Heng Joo Joe Sim | Non Executive Director |
| Mr. Lim Tsin Lin | Non Executive Director |
| Mr. Mehmet Ali Aydinlar | Non Executive Director |
| Mr. Joerg Ayrle | Non Executive Director |
Fortis Healthcare Ltd. Share Price Update | |
|---|---|
| Share Price | Value |
| Today | ₹461.05 |
| Previous Day | ₹452.20 |
FAQ
What is the intrinsic value of Fortis Healthcare Ltd?
Fortis Healthcare Ltd's intrinsic value (as of 17 November 2025) is 715.87 which is 24.17% lower the current market price of 944.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 71,302 Cr. market cap, FY2025-2026 high/low of 1,105/521, reserves of ₹8,162 Cr, and liabilities of 13,377 Cr.
What is the Market Cap of Fortis Healthcare Ltd?
The Market Cap of Fortis Healthcare Ltd is 71,302 Cr..
What is the current Stock Price of Fortis Healthcare Ltd as on 17 November 2025?
The current stock price of Fortis Healthcare Ltd as on 17 November 2025 is 944.
What is the High / Low of Fortis Healthcare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Fortis Healthcare Ltd stocks is 1,105/521.
What is the Stock P/E of Fortis Healthcare Ltd?
The Stock P/E of Fortis Healthcare Ltd is 70.8.
What is the Book Value of Fortis Healthcare Ltd?
The Book Value of Fortis Healthcare Ltd is 125.
What is the Dividend Yield of Fortis Healthcare Ltd?
The Dividend Yield of Fortis Healthcare Ltd is 0.11 %.
What is the ROCE of Fortis Healthcare Ltd?
The ROCE of Fortis Healthcare Ltd is 12.0 %.
What is the ROE of Fortis Healthcare Ltd?
The ROE of Fortis Healthcare Ltd is 10.1 %.
What is the Face Value of Fortis Healthcare Ltd?
The Face Value of Fortis Healthcare Ltd is 10.0.